| 2023-10-06 |
复牌提示：
2023-10-05 19:50:00 停牌，复牌日期 2023-10-09 00:00:01
|
| 2023-08-08 |
详情>>
股本变动：
变动后总股本22899.46万股
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益0.80美元,归母净利润1.82亿美元,同比去年增长-31.47%
|
| 2023-08-08 |
财报披露：
美东时间 2023-08-08 盘前发布财报
|
| 2023-06-30 |
股东大会：
将于2023-07-27召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the three nominees for Class III directors named herein to serve for a term set to expire at the 2026 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our nmed executive officers, as disclosed in this Proxy Statement.
4.To conduct any other business properly brought before the meeting.
|
| 2023-05-03 |
详情>>
业绩披露：
2023年一季报每股收益0.24美元,归母净利润5468.40万美元,同比去年增长-73.23%
|
| 2023-03-01 |
详情>>
业绩披露：
2020年年报每股收益1.91美元,归母净利润3.90亿美元,同比去年增长-31.98%
|
| 2023-03-01 |
详情>>
业绩披露：
2022年年报每股收益2.28美元,归母净利润5.21亿美元,同比去年增长-2.43%
|
| 2023-01-23 |
股东大会：
将于2023-02-24召开股东大会
会议内容 ▼▲
- 1.Scheme Approval Resolution: To approve the Scheme of Arrangement and authorize the directors of Horizon to take all such actions as they consider necessary or appropriate for carrying the Scheme of Arrangement into effect.
2.Articles of Association Amendment Resolution: To amend the Articles of Association of Horizon so that any Horizon Shares that are issued on or after the Voting Record Time to persons other than Acquirer Sub or its nominees will either be subject to the terms of the Scheme or will be immediately and automatically acquired by Acquirer Sub and/or its nominee(s) for the Scheme Consideration.
3.Compensation Resolution: To approve, on a non-binding, advisory basis, specified compensatory arrangements between Horizon and its named executive officers relating to the Transaction.
4.Adjournment Resolution: To approve any motion by the Chairman to adjourn the EGM, or any adjournments thereof, to another time and place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the EGM to approve the Scheme Approval Resolution and the Articles of Association Amendment Resolution.
|
| 2022-11-02 |
详情>>
业绩披露：
2022年三季报(累计)每股收益1.75美元,归母净利润4.01亿美元,同比去年增长11.01%
|
| 2022-08-03 |
详情>>
业绩披露：
2022年中报每股收益1.16美元,归母净利润2.65亿美元,同比去年增长662.91%
|
| 2022-05-04 |
详情>>
业绩披露：
2021年一季报每股收益-0.55美元,归母净利润-1.23亿美元,同比去年增长-807.59%
|
| 2022-05-04 |
详情>>
业绩披露：
2022年一季报每股收益0.89美元,归母净利润2.04亿美元,同比去年增长265.59%
|
| 2022-03-17 |
股东大会：
将于2022-04-28召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the three nominees for Class II directors named herein to hold office until the 2025 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
4.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
5.To approve the Amended and Restated 2020 Equity Incentive Plan.
6.To conduct any other business properly brought before the meeting.
|
| 2022-03-01 |
详情>>
业绩披露：
2021年年报每股收益2.37美元,归母净利润5.34亿美元,同比去年增长37.12%
|
| 2021-11-03 |
详情>>
业绩披露：
2021年三季报(累计)每股收益1.61美元,归母净利润3.61亿美元,同比去年增长81.34%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-04 |
详情>>
业绩披露：
2021年中报每股收益0.15美元,归母净利润3476.60万美元,同比去年增长137.14%
|
| 2021-03-17 |
股东大会：
将于2021-04-29召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the three nominees for Class I directors named herein to hold office until the 2024 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
4.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
5.To approve the Amended and Restated 2020 Equity Incentive Plan.
6.To conduct any other business properly brought before the meeting.
|
| 2020-03-18 |
股东大会：
将于2020-04-30召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the three nominees for Class III directors named herein to hold office until the 2023 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
4.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
5.To approve the 2020 Equity Incentive Plan.
6.To approve the 2020 Employee Share Purchase Plan.
7.To conduct any other business properly brought before the meeting.
|
| 2019-04-08 |
股东大会：
将于2019-05-02召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the two nominees for Class II directors named herein to hold office until the 2022 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
4.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
5.To approve an authorized share capital increase from 40,000 and $30,000 to 40,000 and $60,000 by the creation of an additional 300,000,000 ordinary shares of nominal value $0.0001 per share.
6.To renew the Board’s existing authority to allot and issue ordinary shares for cash and non-cash consideration under Irish law.
7.To renew the Board’s existing authority to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply under Irish law.
8.To approve a motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 7.
9.To approve a change of name of our Company to Horizon Therapeutics Public Limited Company.
10.To approve our Amended and Restated 2014 Equity Incentive Plan.
11.To approve our Amended and Restated 2014 Non-Employee Equity Plan.
12.To conduct any other business properly brought before the meeting.
|
| 2018-07-31 |
详情>>
内部人交易：
Karnani Vikram共交易2笔
|
| 2018-04-02 |
股东大会：
将于2018-05-03召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the three nominees for Class I directors named herein to hold office until the 2021 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
4.To indicate, on an advisory basis, the preferred frequency of sharehoder advisory votes on the compensation of our named executive officers.
5.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
6.To approve our Amended and Restated 2014 Equity Incentive Plan.
7.To conduct any other business properly brought before the meeting.
|
| 2017-04-03 |
股东大会：
将于2017-05-03召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions the two nominees for Class III directors named herein to hold office until the 2020 Annual General Meeting of Shareholders.
2.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2017, and to authorize the Audit Committee of our Board of Directors (Board) to determine the auditors’ remuneration.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
4.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
5.To approve an amendment to our Articles of Association to provide that, in the event of a contested director election, directors will be elected by a plurality voting standard.
6.To conduct any other business properly brought before the meeting.
|
| 2016-04-07 |
股东大会：
将于2016-05-03召开股东大会
会议内容 ▼▲
- 1.To elect by separate resolutions the three nominees for Class II directors named herein to hold office until the 2019 Annual General Meeting of Shareholders.
2.To approve an amendment to our Memorandum of Association.
3.To approve an amendment to our Articles of Association.
4.To authorize us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
5.To approve our Amended and Restated 2014 Equity Incentive Plan.
6.To approve the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016 and to authorize the Audit Committee of our Board of Directors to determine the auditors’ remuneration.
7.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
8.To conduct any other business properly brought before the meeting.
|
| 2015-10-15 |
股东大会：
将于2015-11-13召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of up to 81,706,881 ordinary shares, nominal value $0.0001 per share, of Horizon, which we refer to as the Horizon ordinary shares, in connection with an acquisition of Depomed, Inc., whether by way of an exchange offer followed by a second-step merger, a one-step merger transaction (on a negotiated basis) or otherwise. We refer to this proposal as the share issuance proposal.
2.If the share issuance proposal is approved, to approve the increase in the authorized share capital of Horizon from 40,000 and $30,000 to 40,000 and $40,000 by the creation of an additional 100,000,000 Horizon ordinary shares of nominal value $0.0001 per share. We refer to this proposal as the authorized share capital increase proposal.
3.If the authorized share capital increase proposal is approved, to grant the Horizon board of directors, which we refer to as the Horizon Board, an updated authority under Irish law to allot and issue shares, warrants, convertible instruments and options. We refer to this proposal as the directors’ allotment authority proposal.
4.If the directors’ allotment authority proposal is approved, to grant the Horizon Board an updated power under Irish law to issue shares for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance. We refer to this proposal as the pre-emption rights dis-application proposal. We refer to the authorized share capital increase proposal, the directors’ allotment authority proposal and the pre-emption rights dis-application proposal collectively as the additional share capital proposals.
5.To approve any motion to adjourn the extraordinary general meeting, or any adjournments thereof, to another time and place if necessary or appropriate to, among other things, solicit additional proxies if there are insufficient votes at the time of the extraordinary general meeting to approve the share issuance proposal. We refer to this proposal as the adjournment proposal.
|
| 2014-08-08 |
股东大会：
将于2014-09-18召开股东大会
会议内容 ▼▲
- 1.To adopt the Merger Agreement and approve the Merger.
2.To approve, on an advisory basis, certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement.
3.To approve the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan.
4.To approve the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan.
5.To approve the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan.
6.To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to adopt the Merger Agreement and approve the Merger.
7.To conduct any other business properly brought before the meeting.
|
| 2014-06-02 |
股东大会：
将于2014-06-27召开股东大会
会议内容 ▼▲
- 1. To elect the two nominees for Class III Directors named herein to hold office until the 2017 Annual Meeting of Stockholders.
2. To approve an amendment to our 2011 Equity Incentive Plan.
3. To approve, pursuant to NASDAQ Listing Rule 5635, the issuance of shares of our common stock in excess of 13,164,951 shares upon conversion of our 5.00% Convertible Senior Notes due 2018.
4. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2014.
5. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement.
6. To conduct any other business properly brought before the meeting.
|